☆ 4.7 Article

Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Microbiology

Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections

Alba Ruedas-Lopez et al.

Summary: This study aimed to analyze the resistance mechanisms of ceftolozane-tazobactam and ceftazidime-avibactam in multidrug-resistant or extensively drug-resistant P. aeruginosa isolates. The findings revealed that most of the resistant isolates were recovered after treatment with ceftolozane-tazobactam or ceftazidime-avibactam. Chromosomal mutations and specific gene substitutions were identified as the main resistance mechanisms. The study emphasized the potential selection of MDR/XDR P. aeruginosa strains producing certain variants or metallo-beta-lactamases by cephalosporin/beta-lactamase inhibitors, and encouraged judicious use of these agents.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Infectious Diseases

Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa

Laura Corbella et al.

Summary: Limited clinical experience suggests that ceftazidime-avibactam (CAZ-AVI) is a valid alternative for treating multidrug or extremely resistant Pseudomonas aeruginosa infections.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)

添加到收藏夹

Article Infectious Diseases

Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones

Maria A. Gomis-Font et al.

Summary: The study found that resistance development to imipenem/relebactam was slower and reached a lower level compared to ceftolozane/tazobactam in all tested XDR strains. Additionally, imipenem/relebactam resistance remained low even in ST175 isolates that had developed resistance to ceftolozane/tazobactam. Lineages evolved in the presence of ceftolozane/tazobactam exhibited high-level resistance, hypersusceptibility to imipenem/relebactam, and low fitness cost, while lineages evolved in the presence of imipenem/relebactam showed moderate resistance, no cross-resistance to ceftolozane/tazobactam, and high fitness cost.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

添加到收藏夹

Article Infectious Diseases

Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria

Shazad Mushtaq et al.

Summary: Taniborbactam potentiates partner beta-Lactams against various Enterobacterales with different carbapenemases, showing potential broader spectrum compared to vaborbactam.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

添加到收藏夹

Article Infectious Diseases

Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections

Jorge Arca-Suarez et al.

Summary: This study identified that alterations in OXA-10 are involved in the development of resistance to cephalosporin/β-lactamase inhibitor combinations in P. aeruginosa during treatment.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

添加到收藏夹

Article Infectious Diseases

Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory

Shazad Mushtaq et al.

Summary: The study demonstrated that cefepime/zidebactam showed universal susceptibility against multidrug-resistant Enterobacterales, inhibited most Enterobacterales with MBLs, and had enhanced activity against isolates highly resistant to cefepime and zidebactam alone. Additionally, cefepime/zidebactam exhibited good inhibitory effects on Pseudomonas aeruginosa and Acinetobacter baumannii, with the potential to overcome critical resistances in both gram-negative bacteria.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

添加到收藏夹

Article Infectious Diseases

In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy

Isabel Barcelo et al.

Summary: Resistance development to cefepime/zidebactam in Pseudomonas aeruginosa required multiple simultaneous mutations that were associated with significant impairment of fitness and virulence.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

添加到收藏夹

Article Microbiology

Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and lsogenic β-Lactam-Resistant Mutants

Pablo A. Fraile-Ribot et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

添加到收藏夹

Letter Immunology

Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa

Antonio Vena et al.

CLINICAL INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Infectious Diseases

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia

Mercedes Delgado-Valverde et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

添加到收藏夹

Article Infectious Diseases

Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection

Jorge Arca-Suarez et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

添加到收藏夹

Article Microbiology

Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone

Jorge Arca-Suarez et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa

Jodie C. Hamrick et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone

Carla Lopez-Causape et al.

SCIENTIFIC REPORTS (2017)

添加到收藏夹

Review Pharmacology & Pharmacy

The increasing threat of Pseudomonas aeruginosa high-risk clones

Antonio Oliver et al.

DRUG RESISTANCE UPDATES (2015)

添加到收藏夹

Review Infectious Diseases

Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology

Anais Potron et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.